The 2022 National Breast Cancer Conference and the Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Annual Conference opened successfully in Beijing today. The CSCO BC Annual Meeting is one of the most influential academic events in the field of breast cancer in China. The conference will set up special sessions such as “Scientific Frontiers, Drug Research and Development, Diagnosis and Treatment Guidelines, Famous Experts’ Perspectives, and Classified Treatment”, which will be carried out in the form of theme reports, guideline interpretations, hot discussions, and case sharing. The conference invited well-known domestic experts and scholars to give keynote speeches and discussions, and built an academic platform for scholars to exchange and discuss.
Opening Ceremony
Vice Chairman and Secretary General of Chinese Society of Clinical Oncology, General Assembly In his opening speech, Chairman Professor Jiang Zefei expressed his warm welcome and gratitude to the participating experts and colleagues, and introduced the CSCO experts who addressed the opening ceremony. Professor Jiang Zefei said that the development of CSCO BC has received the support and hard work of the leaders and founders of the CSCO Council.
Professor Jiang Zefei >
Professor Ma Jun from Harbin Institute of Hematology and Oncology said in his opening speech that this conference has carefully set up scientific frontiers, new drug development, diagnosis and treatment In the special sessions such as guides and famous experts’ perspectives, well-known experts and scholars in the industry are invited to conduct keynote reports and academic exchanges.
Professor Ma Jun >
Professor Qin Shukui from Jinling Hospital Affiliated to Nanjing University School of Medicine delivered an opening speech. Healthy China is an important national policy at present. Breast cancer is a serious threat to the health and life of human beings, especially women, and it has also received great attention from oncology experts. In recent years, under the leadership of Professor Jiang Zefei and the joint efforts of the members of the CSCO Expert Committee, the CSCO Expert Committee has carried out a series of public welfare academic activities with outstanding achievements. This conference can fully reflect the new progress and new trends in the field of breast cancer, and has become the vane of academic exchanges in the industry.
Professor Qin Shukui >
Science Frontiers Session
Shandong Cancer Hospital in Academician Jin Ming shared issues related to the new practice of precision immunity from the aspects of tumor cells and microenvironment, medical oncology treatment progress, efficacy prediction markers, immune combination strategies, and challenges.
Academician Yu Jinming
Academician Shao Feng of Beijing Institute of Life Sciences explained the original scientific discoveries from innate immunity to pyroptosis to tumor immunity. Academician Shao pointed out that pyroptosis and apoptosis have different mechanisms. GSDME-mediated pyroptosis signaling pathway is an important cause of inflammatory damage caused by chemotherapy or viral infection, and this signaling pathway can induce a strong anti-tumor immune response. And pointed out that the related problems encountered in clinical practice are one of the important research directions of Prof. Shao’s team in the future.
Academician Feng Shao
Professor Jiang Zefei reviewed the development of breast cancer clinical research in China, including the major research progress made by Chinese scholars in the fields of adjuvant, neoadjuvant and advanced treatment, and pointed out that Chinese scholars represent the voice of China. International academic podium, changing the clinical practice of breast cancer treatment in China and even internationally.
Professor Jiang Feize >
Professor Wang Jie from Cancer Hospital, Chinese Academy of Medical Sciences from the development and research history, application status, challenges and directions of liquid biopsy technology He explained the current situation and future of liquid biopsy from each aspect. Professor Wang Jie focused on the four application prospects of liquid biopsy, which can be used to guide treatment, predict efficacy, evaluate drug resistance, early screening and individualized diagnosis. It is widely used in the future. expected.
Dr. Zou Junjian pointed out China’s innovation advantages are concentrated in three aspects: cost, speed and diligence. Since zanubrutinib, China’s first innovative drug “going overseas” achieved zero breakthroughs, new domestic drugs have gone overseas to seek a way out, but the failure of sintilimab reminds us that we should be familiar with FDA rules, Respect the rules and keep in touch with the FDA to improve its international innovation capabilities. High-quality international multi-center clinical research is the stepping stone to open the FDA’s door.
Dr. Zou Jianjun >
Dr. He Jing shared how to choose the appropriate anti-tumor drug in the clinical process of research and development Dr. He Jing analyzed the advantages and disadvantages of the selection of research endpoints from a number of well-known studies in the field of breast cancer, and provided new ideas for further clinical research .
Dr. He Jing
Dr. Chen Xiaoyuan shared how to choose a control group reasonably in the clinical process of new anti-tumor drug development. Randomized controlled trials can avoid possible biases in trial design and implementation to the greatest extent, and are the “gold standard” for verifying efficacy. The selection of the control group should be based on the purpose of the trial, protect the interests of the subjects and the broad patient group, and should understand the advantages and disadvantages of placebo, active control and external control.
Professor Wu strongs<600"> >
Professor Liu Yueping from the Fourth Hospital of Hebei Medical University conducted the pathological part of the new guideline introduced in detail. The update of the pathology section mainly covers the histological types and molecular characteristics of the 2019 WHO version of breast invasive carcinoma, and the evaluation of tumor-infiltrating lymphocytes is added. The pathological assessment of weak ER positive and HER-2 low expression was also emphasized.
Professor Liu Yueping >
Mentioning about radiation therapy for breast cancer, Professor Chen Jiayi of Ruijin Hospital, Shanghai Jiaotong University School of Medicine pointed out that radiation therapy for breast cancer has entered a short-course, new Technology and Precision “Light Era”. Prof. Chen explained in detail the updated key points and related research progress of breast cancer radiotherapy in this year’s new guideline from three aspects: short-course radiotherapy for early breast cancer, progress in local treatment of regional lymph nodes, and optimization of radiotherapy strategies in precision medicine.
Professor Jiayi Chen >
Professor Wang Kun from Guangdong Provincial People’s Hospital shared the 2022 CSCO BC—early triple-negative breast cancer Update points and research progress of cancer. For these patients, adjuvant therapy and adjuvant chemotherapy (intensive therapy) after neoadjuvant therapy for triple-negative breast cancer are mainly added.
Professor Wang Kun
Professor Yin Yongmei of Jiangsu Provincial People’s Hospital explained some updated points of the new guideline for HER2-positive advanced breast cancer. Professor Yin Yongmei pointed out that for the stratification of these patients, this year’s guidelines have added a new stratification for TKI treatment failure. In addition, the original “Hydrogen has never been used, but it is suitable for reuse” has been adjusted to “H sensitive”. Layered.
Professor Mei Yin
Professor Hao Chunfang from Tianjin Medical University Cancer Hospital explained the update points of the latest guidelines for hormone receptor-positive advanced breast cancer And related research progress, Professor Hao pointed out that the endocrine therapy of the 2020 guideline can be summarized as: many changes, fast pace, many expectations, and great challenges; and for the endocrine therapy of this year’s new guideline, it can be summarized as: Layer, advantage screening, comprehensive management, long-term stability.
Professor Hao Chunfang strong>
Professor Wang Shusen from Sun Yat-Sen University Cancer Center explained the update points of triple negative advanced breast cancer and reasons for recommendation. Professor Wang pointed out that chemotherapy is the mainstay of advanced triple-negative breast cancer, and targeted therapy has achieved precise breakthroughs. Based on relevant research, immunotherapy is currently in a state of “ice and fire”, and ADC drugs “the future has come”.
Professor Wang Shusen
Professor Liu Yinhua from Peking University First Hospital interprets the main points of the 2022 edition of the Chinese Medical Association Breast Surgery Clinical Practice Guidelines. The 2022 edition revised content topics include invasiveness Breast cancer, modified radical mastectomy, breast-conserving surgery, sentinel lymph node biopsy, breast cancer during pregnancy and lactation, and central venous access for breast cancer.
Professor Liu Yinhua
at the end of the diagnosis and treatment guidelines During the session, Professor Jiang Zefei explained the main update points of the new guide in a systematic, comprehensive and detailed manner. Professor Jiang pointed out that after the annual review and guideline update discussion held on January 8th this year, the paper guideline was promulgated at the CSCO BC annual meeting on the 8th. At this conference, the CSCO AI BC artificial intelligence assistant decision-making system will be released. In the future, it is hoped that the AI system can be used to realize artificial intelligence, intelligent decision-making and case management.
Professor Jiang Zefei
After the interpretation of the diagnosis and treatment guidelines, Professor Wang Shu of Peking University People’s Hospital and Professor Song Guohong of Peking University Cancer Hospital respectively pointed out The related issues in the field of adjuvant therapy and bone metastases MDT were sorted out, and the experts conducted hot discussions on specific cases.
Professor Wang Shu strong>
Professor Song Guohong
Hot Discussion 2 span>
Press Conference
At the beginning of the meeting During the press conference on Japan, Professor Jiang Zefei first extended a warm welcome to the media friends who attended the press conference. Professor Jiang pointed out that combining China’s reality, formulating China’s guidelines, providing China’s solutions, and solving China’s problems are things that Chinese experts in the field of breast cancer need to accomplish together. Since the first release of the CSCO BC guidelines in 2017, they have been updated in 2019, 2020, and 2021 respectively. The 2022 update of the CSCO breast cancer diagnosis and treatment guidelines mainly covers organizations and expert group members, evidence level and recommendation level, international progress, and Chinese contributions. , Expert Consensus, Accessibility, and Artificial Intelligence and Disease Management.
“img class=”000title” layout responsive” sizes=”(min-width: 320px) 320px, 100vw” src=”https://mmbiz.qpic.cn/mmbiz_png/AtTmw2081JgMGLXSttEj33X1YtnVMyOnxMJDibmnHnnxQk3fG3lutKRsUl9YDibdKVvMmpGia8LV9iavg9uRlzq4Q/640″ width=”600″ content_title” height=”300″ layout=”responsive” sizes=”(min-width: 320px) 320px, 100vw” src=”https://mmbiz.qpic.cn/mmbiz_png/AtTmw2081JgMGLXSttEj33X1YtnVMyOnWgOibItXOTayncgc5MggaJDhyfmjOI2yo2tKRKweZPv5JXe3Oe7width=”60″ >
The experts who attended the press conference included Prof. Yin Yongmei, Prof. Wang Yinhua, Prof. Wang Xiaojia, Prof. Wang Shusen from Zhejiang Cancer Hospital, and Prof. Geng Cuizhi from the Fourth Hospital of Hebei Medical University. They answered questions from various media about the new guideline.
For more exciting things to come…
Editor: XY
Reviewer: XY
Typesetting: Wenting
Execution: Wenting
Famous teacher class, scan the code to enter
< span>▼▼▼
For more courses, please refer to the public account of “Yimaitong Knowledge Bank”